578 related articles for article (PubMed ID: 32993751)
1. Efficacy of tocilizumab in patients with COVID-19 ARDS undergoing noninvasive ventilation.
Menzella F; Fontana M; Salvarani C; Massari M; Ruggiero P; Scelfo C; Barbieri C; Castagnetti C; Catellani C; Gibellini G; Falco F; Ghidoni G; Livrieri F; Montanari G; Casalini E; Piro R; Mancuso P; Ghidorsi L; Facciolongo N
Crit Care; 2020 Sep; 24(1):589. PubMed ID: 32993751
[TBL] [Abstract][Full Text] [Related]
2. Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy.
Toniati P; Piva S; Cattalini M; Garrafa E; Regola F; Castelli F; Franceschini F; Airò P; Bazzani C; Beindorf EA; Berlendis M; Bezzi M; Bossini N; Castellano M; Cattaneo S; Cavazzana I; Contessi GB; Crippa M; Delbarba A; De Peri E; Faletti A; Filippini M; Filippini M; Frassi M; Gaggiotti M; Gorla R; Lanspa M; Lorenzotti S; Marino R; Maroldi R; Metra M; Matteelli A; Modina D; Moioli G; Montani G; Muiesan ML; Odolini S; Peli E; Pesenti S; Pezzoli MC; Pirola I; Pozzi A; Proto A; Rasulo FA; Renisi G; Ricci C; Rizzoni D; Romanelli G; Rossi M; Salvetti M; Scolari F; Signorini L; Taglietti M; Tomasoni G; Tomasoni LR; Turla F; Valsecchi A; Zani D; Zuccalà F; Zunica F; Focà E; Andreoli L; Latronico N
Autoimmun Rev; 2020 Jul; 19(7):102568. PubMed ID: 32376398
[TBL] [Abstract][Full Text] [Related]
3. Rapid and Impressive Response to a Combined Treatment with Single-Dose Tocilizumab and NIV in a Patient with COVID-19 Pneumonia/ARDS.
Cascella M; Mauro I; De Blasio E; Crispo A; Del Gaudio A; Bimonte S; Cuomo A; Ascierto PA
Medicina (Kaunas); 2020 Jul; 56(8):. PubMed ID: 32727107
[TBL] [Abstract][Full Text] [Related]
4. Experience with tocilizumab in severe COVID-19 pneumonia after 80 days of follow-up: A retrospective cohort study.
Moreno-Pérez O; Andres M; Leon-Ramirez JM; Sánchez-Payá J; Rodríguez JC; Sánchez R; García-Sevila R; Boix V; Gil J; Merino E
J Autoimmun; 2020 Nov; 114():102523. PubMed ID: 32690352
[TBL] [Abstract][Full Text] [Related]
5. Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial.
Hermine O; Mariette X; Tharaux PL; Resche-Rigon M; Porcher R; Ravaud P;
JAMA Intern Med; 2021 Jan; 181(1):32-40. PubMed ID: 33080017
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of anti-il6-receptor tocilizumab use in severe and critical patients affected by coronavirus disease 2019: A comparative analysis.
Rossotti R; Travi G; Ughi N; Corradin M; Baiguera C; Fumagalli R; Bottiroli M; Mondino M; Merli M; Bellone A; Basile A; Ruggeri R; Colombo F; Moreno M; Pastori S; Perno CF; Tarsia P; Epis OM; Puoti M;
J Infect; 2020 Oct; 81(4):e11-e17. PubMed ID: 32652164
[TBL] [Abstract][Full Text] [Related]
7. A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial.
Smith K; Pace A; Ortiz S; Kazani S; Rottinghaus S
Trials; 2020 Jul; 21(1):639. PubMed ID: 32660611
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study.
Campochiaro C; Della-Torre E; Cavalli G; De Luca G; Ripa M; Boffini N; Tomelleri A; Baldissera E; Rovere-Querini P; Ruggeri A; Monti G; De Cobelli F; Zangrillo A; Tresoldi M; Castagna A; Dagna L;
Eur J Intern Med; 2020 Jun; 76():43-49. PubMed ID: 32482597
[TBL] [Abstract][Full Text] [Related]
9. A prospective, randomised, double blind placebo-controlled trial to evaluate the efficacy and safety of tocilizumab in patients with severe COVID-19 pneumonia (TOC-COVID): A structured summary of a study protocol for a randomised controlled trial.
Rilinger J; Kern WV; Duerschmied D; Supady A; Bode C; Staudacher DL; Wengenmayer T
Trials; 2020 Jun; 21(1):470. PubMed ID: 32493514
[TBL] [Abstract][Full Text] [Related]
10. Biomarker variation in patients successfully treated with tocilizumab for severe coronavirus disease 2019 (COVID-19): results of a multidisciplinary collaboration.
Conrozier T; Lohse A; Balblanc JC; Dussert P; Royer PY; Bossert M; Bozgan AM; Gendrin V; Charpentier A; Toko L; Badie J; Mezher C; Roux MF; Kadiane-Oussou NJ; Contreras R; Kessler J; Mazurier I; Klopfenstein T; Zayet S
Clin Exp Rheumatol; 2020; 38(4):742-747. PubMed ID: 32573419
[TBL] [Abstract][Full Text] [Related]
11. High dose subcutaneous Anakinra to treat acute respiratory distress syndrome secondary to cytokine storm syndrome among severely ill COVID-19 patients.
Iglesias-Julián E; López-Veloso M; de-la-Torre-Ferrera N; Barraza-Vengoechea JC; Delgado-López PD; Colazo-Burlato M; Ubeira-Iglesias M; Montero-Baladía M; Lorenzo-Martín A; Minguito-de-la-Iglesia J; García-Muñoz JP; Sanllorente-Sebastián R; Vicente-González B; Alemán-Alemán A; Buzón-Martín L
J Autoimmun; 2020 Dec; 115():102537. PubMed ID: 32843231
[TBL] [Abstract][Full Text] [Related]
12. Impact of tocilizumab on mortality and/or invasive mechanical ventilation requirement in a cohort of 206 COVID-19 patients.
Klopfenstein T; Zayet S; Lohse A; Selles P; Zahra H; Kadiane-Oussou NJ; Toko L; Royer PY; Balblanc JC; Gendrin V; Conrozier T;
Int J Infect Dis; 2020 Oct; 99():491-495. PubMed ID: 32798660
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of noninvasive ventilation in COVID-19 related-acute respiratory distress syndrome.
Menzella F; Barbieri C; Fontana M; Scelfo C; Castagnetti C; Ghidoni G; Ruggiero P; Livrieri F; Piro R; Ghidorsi L; Montanari G; Gibellini G; Casalini E; Falco F; Catellani C; Facciolongo N
Clin Respir J; 2021 Jul; 15(7):779-787. PubMed ID: 33728822
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of tocilizumab in the treatment of severe acute respiratory syndrome coronavirus-2 pneumonia: A retrospective cohort study.
Patel A; Shah K; Dharsandiya M; Patel K; Patel T; Patel M; Reljic T; Kumar A
Indian J Med Microbiol; 2020; 38(1):117-123. PubMed ID: 32719218
[TBL] [Abstract][Full Text] [Related]
15. Tocilizumab therapy reduced intensive care unit admissions and/or mortality in COVID-19 patients.
Klopfenstein T; Zayet S; Lohse A; Balblanc JC; Badie J; Royer PY; Toko L; Mezher C; Kadiane-Oussou NJ; Bossert M; Bozgan AM; Charpentier A; Roux MF; Contreras R; Mazurier I; Dussert P; Gendrin V; Conrozier T;
Med Mal Infect; 2020 Aug; 50(5):397-400. PubMed ID: 32387320
[TBL] [Abstract][Full Text] [Related]
16. Flow controlled ventilation in Acute Respiratory Distress Syndrome associated with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Roehrig S; Ait Hssain A; Shallik NAH; Elsaid IMA; Mustafa SF; Smain OAM; Molokhia AA; Lance MD
Trials; 2020 Sep; 21(1):781. PubMed ID: 32917259
[TBL] [Abstract][Full Text] [Related]
17. Low-dose subcutaneous tocilizumab to prevent disease progression in patients with moderate COVID-19 pneumonia and hyperinflammation.
Potere N; Di Nisio M; Rizzo G; La Vella M; Polilli E; Agostinone A; Spacone A; Di Carlo S; Costantini A; Abbate A; Porreca E; Parruti G
Int J Infect Dis; 2020 Nov; 100():421-424. PubMed ID: 32768701
[TBL] [Abstract][Full Text] [Related]
18. The role of tocilizumab therapy in critically ill patients with severe acute respiratory syndrome coronavirus 2.
Saffo Z; Guo W; Springer K; Maksimowicz-McKinnon K; Kak V; McKinnon JE; Bhargava P
J Osteopath Med; 2021 Jul; 121(8):705-714. PubMed ID: 34237804
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-6 receptor blocking with intravenous tocilizumab in COVID-19 severe acute respiratory distress syndrome: A retrospective case-control survival analysis of 128 patients.
Canziani LM; Trovati S; Brunetta E; Testa A; De Santis M; Bombardieri E; Guidelli G; Albano G; Folci M; Squadroni M; Beretta GD; Ciccarelli M; Castoldi M; Lleo A; Aghemo A; Vernile L; Malesci A; Omodei P; Angelini C; Badalamenti S; Cecconi M; Cremonesi A; Selmi C;
J Autoimmun; 2020 Nov; 114():102511. PubMed ID: 32713677
[TBL] [Abstract][Full Text] [Related]
20. Recovery of COVID-19 acute respiratory distress syndrome with tocilizumab: successful outcome in two critically ill patients.
Cala-García JD; Sierra-Bretón JD; Cavelier-Baiz JE; Faccini-Martínez ÁA; Pérez-Díaz CE
Immunotherapy; 2020 Oct; 12(15):1127-1132. PubMed ID: 32664810
[No Abstract] [Full Text] [Related]
[Next] [New Search]